Could this hepatitis-B vaccine turn into a diabetes play?
A bull's view of Dendreon's conference presentation.
Is this an opportunity to invest in high-flying Regeneron?
We get to see some key metrics from MAKO's Q4 before the company officially releases earnings.
Great news for investors in the enormous diabetes market.
Dendreon releases preliminary quarterly results.
Anything less than perfection doesn't cut it
Turning clinical data lemons into lemonade.
Who's buying Bausch & Lomb?
One big up and one big down in the biotech space today.
This Biotech ETF isn't my best bet.
If you're going the ETF route, this product appears to be the best option
Too risk averse for biotech? These big pharmas could be your ticket.
What are the biggest overhangs facing this biotech company?
As payer's increasingly scrutinize costs, will these companies lose out?
Now that Abbott Labs has slimmed down and lost its branded pharmaceuticals division by spinning off the new AbbVie, what should investors make of it?
The Abbott Labs spin-off AbbVie is officially on the market.
Time to part ways?
Without the Mayans, we need a new apocalypse to worry about. Why not robots? Medical robots, to be exact.
Will MAKO Surgical also suffer at the hands of this bear?